Takeda Pharmaceutical is expected to have
tripled its Q4 profit, sparking interest from various investment groups. Despite recent fluctuations in its stock, retail investors hold its largest shareholder sector at
51%, with
institutions owning 48%. The performance of Takeda against its rival Viatris has triggered debates among investors, with certain strong selling activities noted. However, the general consensus is that
Takeda’s stock is undervalued and ripe for turnaround. Dividends are appealing, with an ultra-cheap option for high-yield dividends available; its shareholders have reportedly seen an 8.8% CAGR over the last three years. Despite a drop in full-year profit forecasts, Takeda has been recommended as a strong buy, with various businesses increasing their stake in the company. The FDA's approval of Eohilia has provided a boost, though pipeline expansion uncertainties persist. Analysts, overall, express belief in the potential
26% upside in Takeda stock. Notably, the company's major $62 billion Shire deal and the proposed sale of Japan health business to
Blackstone have gained significant traction.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Thu, 09 May 2024 23:34:05 GMT -
Rating 5
- Innovation -2
- Information 7
- Rumor -3
